Homoharringtonine for the treatment of chronic myelogenous leukemia

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 6, 2008, Pages 1029-1037

  Quintás Cardama, Alfonso ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myelogenous leukemia; Homoharringtonine; Omacetaxine mepesuccinate; T315I mutation

Indexed keywords

ALPHA INTERFERON; CEPHALOTAXINE; CGX 653; CYTARABINE; EARLY GROWTH RESPONSE FACTOR; HOMOHARRINGTONINE; IMATINIB; MYELOSTAT; OMACETAXINE MEPESUCCINATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR GATA; TRANSCRIPTION FACTOR PAX2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENE OVEREXPRESSION; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

EID: 42649143835     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.6.1029     Document Type: Review

References (51)

1. Powell RG, Weisleder D, Smith CR Jr. Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci 1972;61:1227-30
2. Kantarjian HM, Talpaz M, Santini V, et al. Homoharringtonine: history, current research, and future direction. Cancer 2001;92:1591-605
3. Harringtonine in acute leukemias. Clinical analysis of 31 cases. Chin Med J (Engl) 1977;3:319-24
4. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J (Engl) 1976;2:263-72
5. O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995;86:3322-6
6. O'Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999;93:4149-53
7. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6
8. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
9. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80
10. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401
11. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41
12. Powell RG, Weisleder D, Smith CR Jr, Rohwedder WK. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett 1970;11:815-8
13. Robin J, Dhal R, Dujardin G, et al. The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety. Tetrahedron Lett 1999;40:2931-4
14. Fresno M, Jimenez A, Vazquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 1977;72:323-30
15. Kuliczkowski K. Influence of harringtonine on human leukemia cell differentiation. Arch Immunol Ther Exp (Warsz) 1989;37:69-76
16. Yinjun L, Jie J, Weilai X, Xiangming T. Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol 2004;76:199-204
17. Baaske DM, Heinstein P. Cytotoxicity and cell cycle specificity of homoharringtonine. Antimicrob Agents Chemother 1977;12:298-300
18. Visani G, Russo D, Ottaviani E, et al. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia 1997;11:624-8
19. Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006;5:723-31
20. Kuroda J, Kimura S, Andreeff M, et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 2008;140:181-90
21. Lou YJ, Qian WB, Jin J. Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma 2007;48:1400-6
22. Jin W, Wu J, Zhuang Z, et al. Gene expression profiling in apoptotic k562 cells treated by homoharringtonine. Acta Biochim Biophys Sin (Shanghai) 2007;39:982-91
23. Michaels S, Brown D, Segal D. Analysis of transcription factor expression after homoharringtonine treatment. Proc Amer Assoc Cancer Res 2007;48:(abstract 4843)
24. Efferth T, Sauerbrey A, Olbrich A, et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003;64:382-94
25. Russo D, Michelutti A, Melti C, et al. MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine. Leukemia 1995;9:513-6
26. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007;1775:237-62
27. Tipping AJ, Mahon FX, Zafirides G, et al. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002;16:2349-57
28. Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001;97:1999-2007
29. Scappini B, Onida F, Kantarjian HM, et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 2002;94:2653-62
30. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006;66:10959-66
31. Newman K, Meeks RG, Denine EP, et al. Final phase II report of task I: preclinical intravenous toxicity study of homoharringtonine (NSC: 141633) in CDF, mice and beagle dogs. Bethesda (MD): the Division of Cancer Treatment, National Cancer Institute; 1981
32. Ni D, Ho DH, Vijjeswarapu M, et al. Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia. J Exp Ther Oncol 2003;3:47-52
33. Lu K, Savaraj N, Feun LG, et al. Pharmacokinetics of homoharringtonine in dogs. Cancer Chemother Pharmacol 1988;21:139-42
34. Levy V, Zohar S, Bardin C, et al. A phase 1 dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 2006;95:253-9
35. Brown D, Michaels S. Design and evaluation of oral delivery dosage forms of homoharringtonine. Proc Amer Assoc Cancer Res 2007;48:(abstract 4730)
36. Coonley CJ, Warrell RP Jr, Young CW. Phase I trial of homoharringtonine administered as a 5-day continuous infusion. Cancer Treat Rep 1983;67:693-6
37. Neidhart JA, Young DC, Kraut E, et al. Phase I trial of homoharringtonine administered by prolonged continuous infusion. Cancer Res 1986;46:967-9
38. Malamud S, Ohnuma T, Coffey V, et al. Phase I study of homoharringtonine (HHT) in 10 day schedule: 6 hour infusion daily vs. continuous infusion. Proc Amer Assoc Cancer Res 1984;25:(abstract 1799)
39. Legha SS, Keating M, Picket S, et al. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 1984;68:1085-91
40. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy Cancer 2007;109:248-55
41. Ernst T, Vance E, Alyea E III, et al. Homoharringtonine and low-dose ara-C is a highly effective combination for the treatment of CML in chronic phase. Blood 1997;90:(abstract) p571a
42. Kantarjian HM, Talpaz M, Smith TL, et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol 2000;18:3513-21
43. O'Brien S, Giles F, Talpaz M, et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 2003;98:888-93
44. O'Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 2002;94:2024-32
45. Burton C, Ranger A, Nadal E, et al. Semi-synthetic homoharringtonine (Myelostat(R)) for chronic myeloid leukemia in accelerated phase after imatinib failure. Blood 2003;102:(abstract pp 908a-909a)
46. Maloisel F, Rousselot P, Morariu R. Subcutaneous hemi-synthetic homoharringtonine (HHT) in combination with imatinib mesylate (Gleevec) in patients (PTS) with STI-resistant chronic myelogenous leukemia (CIVIL): Preliminary results of a pilot study. Blood 2003;102:(abstract pp. 909a)
47. Marin D, Kaeda JS, Andreasson C, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005;103:1850-5
48. Quintas-Cardama A, Kantarjian H, Wierda W, et al. A phase II study of intravenous (IV) homoharringtonine (HHT) and imatinib (IM) in patients (pts) with chronic myeloid leukemia (CML). Blood 2006; 108:(abstract 2174)
49. de Lavallade H, Khorashad JS, Davis HP, et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007;110:2779-80
50. Legros L, Hayette S, Nicolini FE, et al. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia 2007;21:2204-6
51. Khoury H, Michallet M, Corm S, et al. Safety and Efficacy Study of Subcutaneous Homoharringtonine (SC HHT) in Imatinib (IM)-Resistant Chronic Myeloid Leukemia (CML) with the T315I Mutation Initial Report of a Phase II Trial. Blood 2007;110:(abstract 1050)